Novo Nordisk reports 22% weight loss with amycretin
5 days ago · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the …
Novo Nordisk’s Amycretin Achieves Up to 22% Weight Loss in …
Jan 24, 2025 · Novo Nordisk reported today that amycretin, an investigational glucagon-like peptide-1 (GLP-1) and amylin receptor agonist, led to significant weight reductions in …
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight ...
6 days ago · Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals. ... Subjects receiving the therapy …
Novo Nordisk next-gen shot shows 22% weight loss in early results
Jan 24, 2025 · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial …
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
Jan 24, 2025 · Novo Nordisk unveiled topline Phase Ib/IIa data Friday for its next-generation obesity treatment amycretin, which elicited up to 22% weight-loss in adults with overweight or …
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection …
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo Nordisk …
Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same …
Daily pill cuts body weight by up to 13% after 3 months in
Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday …
Weight loss: Amycretin pill may be more effective than semaglutide
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have …